33.76
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
TG Therapeutics Inc. stock chart pattern explained2025 Technical Overview & Technical Buy Zone Confirmation - newser.com
How risky is TG Therapeutics Inc. (NKB2) stock compared to peers2025 Growth vs Value & Daily Stock Trend Reports - newser.com
Is TG Therapeutics Inc. stock bottoming outJuly 2025 Market Mood & High Yield Equity Trading Tips - newser.com
Market reaction to TG Therapeutics Inc.’s recent newsMarket Performance Recap & Risk Controlled Stock Alerts - newser.com
What makes TG Therapeutics Inc. (NKB2) stock appealing to growth investorsMarket Risk Analysis & High Return Stock Watch Alerts - newser.com
Is TG Therapeutics Inc. still worth holding after the dipJuly 2025 Retail & Verified Chart Pattern Trade Signals - newser.com
Is TG Therapeutics Inc. reversing from oversold territoryMarket Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
What indicators show strength in TG Therapeutics Inc.Dividend Hike & Expert Approved Momentum Trade Ideas - newser.com
Analysts Offer Predictions for TG Therapeutics Q3 Earnings - MarketBeat
What analysts say about TG Therapeutics Inc stockEarnings Forecast Updates & Identify Breakout Stocks - earlytimes.in
TG Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
HC Wainwright Weighs in on TG Therapeutics FY2029 Earnings - MarketBeat
TG Therapeutics raises 2025 guidance to $560M, driven by BRIUMVI adoption - MSN
Is TG Therapeutics Inc. forming a bottoming baseMarket Performance Report & Reliable Entry Point Alerts - newser.com
TGTX Receives 'Buy' Rating from HC Wainwright & Co. with $60 Pri - GuruFocus
Analyzing TG Therapeutics Inc. with risk reward ratio chartsQuarterly Performance Summary & Fast Entry and Exit Trade Plans - newser.com
Detecting support and resistance levels for TG Therapeutics Inc.July 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$176m market cap gain - Yahoo Finance
What TG Therapeutics (TGTX)'s Six-Year BRIUMVI Safety Data Means For Shareholders - Yahoo Finance
A Look at TG Therapeutics (TGTX) Valuation Following Positive Six-Year BRIUMVI Trial Results - Sahm
TG Therapeutics, Inc.'s (NASDAQ:TGTX) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 5.8% Over Last Week - 富途牛牛
Key metrics from TG Therapeutics Inc.’s quarterly dataTrade Volume Summary & Precise Buy Zone Identification - newser.com
Can TG Therapeutics Inc. stock rebound after recent weaknessBear Alert & Real-Time Stock Movement Alerts - newser.com
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You - Sahm
Is TG Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Rallies & Short-Term High Return Strategies - newser.com
TG Therapeutics, Inc. (TGTX) Investor Outlook: Strong Revenue Growth and Promising Pipeline Signal Potential Upside - DirectorsTalk Interviews
TG Therapeutics, Inc. (TGTX) Investor Outlook: Riding On A 92.10% Revenue Growth Wave - DirectorsTalk Interviews
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
What drives TG Therapeutics Inc stock priceGlobal Trade Effects & Low Risk Capital Growth Plans - earlytimes.in
Is TG Therapeutics Inc a good long term investmentHead and Shoulders Patterns & Demo Trading Rooms Open Daily - Early Times
TG Therapeutics (TGTX) Is Up 9.7% After Six-Year BRIUMVI MS Data Shows Sustained Efficacy and Safety - Sahm
Tg Therapeutics And Ke Holdings Top The Bull Strangle Watch List For This Week - Barchart.com
TG Therapeutics’ MS drug shows low relapse rate after six years - Investing.com Nigeria
TG Therapeutics’ MS drug shows low relapse rate after six years By Investing.com - Investing.com South Africa
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):